Premium
Clopidogrel‐Induced Hepatotoxicity and Fever
Author(s) -
Ng Jennifer A.,
Goldberg Neil,
Tafreshi Mohammad J.
Publication year - 2006
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.26.7.1023
Subject(s) - clopidogrel , medicine , discontinuation , ticlopidine , liver enzyme , percutaneous coronary intervention , drug , cardiology , gastroenterology , myocardial infarction , pharmacology
A 59‐year‐old woman developed fever and elevated hepatic enzyme levels within days of starting clopidogrel, which had been prescribed in conjunction with a percutaneous coronary intervention. When she discontinued the clopidogrel, her liver enzyme levels returned to baseline and her fever disappeared. These signs and symptoms returned after rechallenge with clopidogrel. Monitoring for fever and elevation of liver enzyme levels in patients taking clopidogrel may be warranted. If a patient has signs of hepatotoxicity with or without fever, discontinuation of clopidogrel should be considered, along with substitution with ticlopidine if clinically warranted.